Ernst & Young: “Optionality” Here To Stay, As Biotech Business Model Reinvents Itself
This article was originally published in The Pink Sheet Daily
Executive Summary
Chaos in the capital markets may force shortened R&D timelines that result in structured acquisitions, novel deal structures, and a boom in personalized medicine.